Celprogen Inc., a leader in the Stem Cell Research and Therapeutics industry for the development of stem cell technologies for regenerative medicine, today announced that they have developed STEMC5007, a synthetic molecule that is capable of stimulating and activating the internal stem cell population. This molecule can be administered by the following methods: intravenous, intra-peritoneal and intramuscular injections, and oral doses.
http://ift.tt/1NZd4hh
http://ift.tt/1NZd4hh
No comments:
Post a Comment